Occurrence of second primary cancer after curative resection of cholangiocarcinoma: a report of 5 cases

Hao Long; Menghao Wang; Jianping Gong; Lan Hu

doi:10.18203/2349-2902.isj20171157

Authors

Hao Long Department of Surgery, Dazu District People's Hospital, Chongqing, China
Menghao Wang Chongqing Key Laboratory of Hepatobiliary Surgery, Department of Hepatobiliary Surgery, Second Affiliated Hospital, Chongqing Medical University, Chongqing, P. R. China
Jianping Gong Chongqing Key Laboratory of Hepatobiliary Surgery, Department of Hepatobiliary Surgery, Second Affiliated Hospital, Chongqing Medical University, Chongqing, P. R. China
Lan Hu Department of Surgery, Dazu District People's Hospital, Chongqing, China

DOI:

https://doi.org/10.18203/2349-2902.isj20171157

Keywords:

Curative resection, Cholangiocarcinoma, Second primary cancer

Abstract

The second primary cancer, a new cancer subsequent to the initial cancer, usually occurs in a person who has a history of cancer or the patient treated with curative resection. Although the pathogenesis of second primary cancer is unclear, it is always found that occurrence of second primary cancer is related to the age and family history. In our 5 cases’ reports, second primary cancer occurs after curative resection of cholangiocarcinoma. And most of the second primary cancers belong to well differentiated adenocarcinomas which grow slowly and never metastasize distally in early stage. Therefore, operative excision is the most effective treatment. At the same time, conventional examination after operation could improve early diagnosis and timely surgical treatment.

Metrics

Metrics Loading ...

References

Kebudi R, Ozdemir GN. Second malignant neoplasms in childhood cancer survivors. Curr Pediatr Rev. 2016.

Murray L, Henry A, Hoskin P. Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol. 2013;8:172.

Razavi P, Rand KA, Cozen W. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013;3(6):121.

Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017. doi:10.1038/nrgastro.2016.193.

Brandi G, Venturi M, Pantaleo MA. Cholangiocarcinoma: current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016;48(3):231-41.

Oliveira ML, Cunningham SC, Cameron JL. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755-62.

Li SQ, Liang LJ, Hua YP. Long-term outcome and prognostic factors of intrahepatic cholangio carcinoma. Chinese Medical Journal. 2009;122(19):2286-91.

Kim JH, Lee YG, Lee J. A case of combined hepatocellular cholangio-carcinoma with sarcomatous transformation and second primary colon cancer. Korean J Hepatol. 2004;10(2):142-7.

Kleinerman RA, Yu CL, Little MP. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30(9):950-7.